<p> The Jammu-based Indian Institute of Integrative Medicine has received approval for clinical trials of its anti-cancer drug IIIM-290, to be used against pancreatic cancer, after successful completion of the preclinical development, the CSIR said on Monday.</p>.<p>The IIIM is a constituent of the Council for Scientific and Industrial Research.</p>.<p>The approval was given by the New Drugs Division of Central Drugs Standard Control Organisation, the CSIR said in a statement.</p>.<p>"The proposed clinical trial is aimed to assess the safety, tolerability and exposure of the compound in humans along with the early efficacy indicators in pancreatic cancer patients," it added.</p>.<p>This drug was discovered and developed at the natural-products driven drug discovery programme of CSIR-IIIM. </p>
<p> The Jammu-based Indian Institute of Integrative Medicine has received approval for clinical trials of its anti-cancer drug IIIM-290, to be used against pancreatic cancer, after successful completion of the preclinical development, the CSIR said on Monday.</p>.<p>The IIIM is a constituent of the Council for Scientific and Industrial Research.</p>.<p>The approval was given by the New Drugs Division of Central Drugs Standard Control Organisation, the CSIR said in a statement.</p>.<p>"The proposed clinical trial is aimed to assess the safety, tolerability and exposure of the compound in humans along with the early efficacy indicators in pancreatic cancer patients," it added.</p>.<p>This drug was discovered and developed at the natural-products driven drug discovery programme of CSIR-IIIM. </p>